Lista de obras - Paul Foster - Dominio Público Uruguay

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

artículo científico publicado en 2008

1H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues

scientific article published on 31 July 2019

A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses

artículo científico publicado en 2000

A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.

artículo científico publicado en 2008

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

artículo científico publicado en 2008

Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography

artículo científico publicado en 2008

Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

artículo científico publicado en 2004

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

artículo científico publicado en 2009

C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression

artículo científico publicado en 2005

Chimeric microtubule disruptors

artículo científico publicado en 2010

Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors

artículo científico publicado en 2016

Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

artículo científico publicado en 2008

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer

artículo científico publicado en 2007

Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor.

artículo científico publicado en 2003

Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER.

artículo científico publicado en 2017

Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy

artículo científico publicado en 2017

In touch with your feminine side: how oestrogen metabolism impacts prostate cancer

artículo científico publicado en 2016

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer

artículo científico publicado en 2014

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

artículo científico publicado en 2006

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol

artículo científico publicado en 2007

NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice.

artículo científico publicado en 2017

Oestrogen and colorectal cancer: mechanisms and controversies ⬇️

artículo científico publicado el 15 de enero de 2013

Recent developments of steroid sulfatase inhibitors as anti-cancer agents.

artículo científico publicado en 2008

STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.

artículo científico publicado en 2008

STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice

artículo científico publicado en 2013

STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model

artículo científico publicado en 2013

Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers

artículo científico publicado en 2012

Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents

artículo científico publicado en 2008

The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression

artículo científico publicado en 2015

The Regulation of Steroid Action by Sulfation and Desulfation

artículo científico publicado en 2015

The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy

artículo científico publicado en 2009

The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.

artículo científico publicado en 2008

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers

artículo científico publicado en 2007

The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer

artículo científico publicado en 2008

Lista de obras de Paul Foster

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

1H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues

A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses

A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography

Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression

Chimeric microtubule disruptors

Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors

Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer

Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor.

Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER.

Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy

In touch with your feminine side: how oestrogen metabolism impacts prostate cancer

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol

NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice.

Oestrogen and colorectal cancer: mechanisms and controversies ⬇️

Recent developments of steroid sulfatase inhibitors as anti-cancer agents.

STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.

STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice

STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model

Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers

Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents

The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression

The Regulation of Steroid Action by Sulfation and Desulfation

The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy

The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers

The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer